439094-96-9

Basic information

• Product Name: 2,4-BIS(TRIFLUOROMETHYL)IMIDAZO[1,2-A][1,8]NAPHTHYRIDINE-8-CARBOXYLIC ACID
• Synonyms: 2,4-BIS(TRIFLUOROMETHYL)IMIDAZO[1,2-A][1,8]NAPHTHYRIDINE-8-CARBOXYLIC ACID;2,4-Bis(trifluoromethyl)-8-carboxyimidazo[1,2-a][1,8]naphthyridine
• CAS NO: 439094-96-9
• Molecular Formula: C₁₃H₅F₆N₃O₂
• Molecular Weight: 349.19
• Mol File: 439094-96-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 281-283°C
• Appearance: /
• CAS DataBase Reference: 2,4-BIS(TRIFLUOROMETHYL)IMIDAZO[1,2-A][1,8]NAPHTHYRIDINE-8-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-BIS(TRIFLUOROMETHYL)IMIDAZO[1,2-A][1,8]NAPHTHYRIDINE-8-CARBOXYLIC ACID(439094-96-9)
• EPA Substance Registry System: 2,4-BIS(TRIFLUOROMETHYL)IMIDAZO[1,2-A][1,8]NAPHTHYRIDINE-8-CARBOXYLIC ACID(439094-96-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 439094-96-9(Hazardous Substances Data)

Usage

General Description

2,4-Bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylic acid is a chemical compound with a complex structure. It is a derivative of imidazo[1,2-a][1,8]naphthyridine, containing two trifluoromethyl groups and a carboxylic acid functional group. The compound has potential pharmaceutical and biological applications due to its unique structure, which may be involved in interactions with specific targets in the body. Its properties and potential uses make it of interest to researchers and pharmaceutical companies for further exploration and development.

Upstream product

• 51420-72-5 7-amino-2,4-bis(trifluoromethyl)-1,8-naphthyridine 
• 1420681-37-3 ethyl 2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate 
• 141-86-6 2.6-diaminopyridine 
• 1522-22-1 1,1,1,5,5,5-hexafluoroacetylacetone 

Relevant articles and documents

Development of an anti-hepatitis B virus (HBV) agent through the structure-activity relationship of the interferon-like small compound CDM-3008

Hepatitis B, a viral infectious disease caused by hepatitis B virus (HBV), is a life-threatening disease that leads liver cirrhosis and liver cancer. Because the current treatments for HBV, such as an interferon (IFN) formulation or nucleoside/nucleotide

IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS

The present disclosure relates to agonists of interferon alpha and beta receptor subunit 2 (IFNAR2) for use in the treatment or prevention of viral disease, particularly COVID-19. In particular embodiments, COVID-19 is associated with pneumonia or acute respiratory distress syndrome (ARDS). In other aspects, the subject being treated is undergoing extra-corporeal membrane oxygenation, mechanical ventilation, non-invasive ventilation, receiving oxygen therapy or receiving antiviral or steroid treatment.